Key result
Recalibration of a high-sensitivity cardiac troponin T assay resulted in an upward shift in concentrations, decreasing the proportion of undetectable results (<5 ng/L) from 30.2% to 1.9%.
Why the study?
Does the recalibration of the hs-cTnT assay alter the measured troponin concentrations in elderly patients?
Does the recalibration of the hs-cTnT assay alter the measured troponin concentrations in elderly patients?
Answers are grounded in this paper and cite their sources.
Recalibration of the Roche hs-cTnT assay introduces a positive bias of approximately 6 ng/L at low concentrations, which will dramatically decrease the percentage of undetectable results and may impact clinical classification.
To the Editor: We read with great interest the letter published in September by Apple and Jaffe regarding the recent adjustment to the calibration of a high-sensitivity cardiac troponin T (hs-cTnT)1 assay (1). The authors raised several important questions regarding the clinical implications of this assay recalibration and pointed out that no correlation studies had been performed for the earlier and new reagent lots. Although we received no information from Roche Diagnostics in France, we observed a shift in the distribution of troponin T concentrations in our university hospital laboratory when we used new reagent lot 167650 instead of lot 164776. Indeed, the overall percentage of the results below the limit of detection (LoD) (<5 ng/L) decreased from 22.7% (from May 1 to June 15, 2012; n = 3696) to 5.8% (from June 20 to July 30, 2012; n = 3097), and the median reported concentration increased from 25.3 ng/L to 29.8 ng/L. We thus decided to measure hs-cTnT with the former and recalibrated lots (lot numbers 164776 and 167650, respectively) in samples available from a cohort of 311 elderly patients [median (interquartile range), 81.5 years (75.8–84.9 years)]. These samples had been frozen at −80 °C before analysis. The study was approved by the ethics committee of Montpellier, informed consent was obtained from all patients, and the collection was registered in the Ministère de la Recherche (DC-2008–417). Although this population cannot be considered a healthy reference population, the differences observed between the measurements with each reagent lot provided preliminary information on the consequences of this recalibration for concentrations ≤100 ng/L. First, use of the former nonrecalibrated lot produced hs-cTnT concentrations <5 ng/L in 94 patients (30.2%); however, only 6 patients had results below the LoD for the same samples measured with the recalibrated reagent lot [median (interquartile range), 8.9 ng/L (7.4–9.5 ng/L); maximum concentration, 11.8 ng/L]. We used Passing–Bablok regression to compare the results obtained with recalibrated and earlier lots (Fig. 1). We obtained the following relationship: y = 0.93x + 6.18 ng/L (Pearson r = 0.992), where y is the hs-cTnT value obtained with lot 167650 and x is the hs-cTnT value obtained with lot 164773. The median between-lot difference in concentration was 5.8 ng/L at 5–8 ng/L, 5.2 ng/L at 8–20 ng/L, and 4.2 ng/L at 20–50 ng/L. Black line represents the line of identity. Red line indicates the Passing–Bablok regression line (y = 0.93x + 6.18 ng/L) used to evaluate the relationship between the reagent lots. Gray zone represents the 95% CI for regression, determined via bootstrapping (1000 bootstraps). These results are consistent with the information provided by Roche Diagnostics and seem to indicate a bias of approximately 6 ng/L for low concentrations that decreases slightly as the troponin T concentration increases. Bias was also observed for concentrations >20 ng/L up to 70 ng/L. Because the bias was quite large for concentrations of 5–20 ng/L, the distribution of hs-cTnT concentrations measured in healthy populations after recalibration is likely to shift upward. This shift carries many implications, which Apple and Jaffe have listed. The percentage of concentrations below the LoD will likely decrease dramatically. As Apple and Jaffe have pointed out, a progressive increase in the percentage of undetectable results has been observed over the past few years, and the Roche calibration correction likely will yield many more samples with detectable concentrations. The design of our study, however, does not allow us to speculate about a potential shift of the 99th percentile value, because troponin concentrations will be higher in older patients. Apple et al. recently reevaluated the 99th percentile with a new lot (lot 167345) and reported a 99th percentile value very close to 14 ng/L (2). Applying the formula obtained from our correlation analysis to routine results measured in our laboratory with the earlier lot gave a corrected distribution with a median of 29.6 ng/L. Although use of this conversion formula allows correction of bias due to the recalibration, this process does not allow recalculation of concentrations that are below the LoD. Furthermore, recalculation of concentrations with the new calibration curve is not straightforward. hs-cTnT is calibrated with a stored 5-point master curve (3), which is not available to users, and a 2-point on-site calibration. Recalculation from calibration curves requires access to raw measurement data, which are not easily available. Although the results of recalibration have been suggested to be independent of reagent lot (4), whether the calibration issues remained constant across the incriminated lots is unknown. Because recalibration of troponin assays could have major implications for patient care (including the classification of acute coronary syndrome) going forward, manufacturers need to provide accurate information to users proactively and transparently. In addition, determination of a lot-to-lot reference change value for use with an external quality control around the 99th percentile could help users appreciate the biological relevance of changes in reagent lots. high-sensitivity cardiac troponin T (assay) limit of detection.
No takes yet. Share an insight, caveat, or question.
Kuster et al. (2013) conducted a letter in Elderly patients (n=311). Recalibrated hs-cTnT assay (lot 167650) vs. Former nonrecalibrated hs-cTnT assay (lot 164776) was evaluated on Percentage of results below the limit of detection (<5 ng/L). Recalibration of a high-sensitivity cardiac troponin T assay resulted in an upward shift in concentrations, decreasing the proportion of undetectable results (<5 ng/L) from 30.2% to 1.9%.
Synapse has enriched 10 related papers. Consider them for comparative context: